Maravai Lifesciences Holdings annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Maravai Lifesciences Holdings Stock-Based Compensation Growth & History (MRVI)
Maravai Lifesciences Holdings's stock-based compensation was $30.2M for fiscal 2025.
View full Maravai Lifesciences Holdings company overviewMaravai Lifesciences Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $30.2M | −$19.2M | −38.94% |
| 2024 | 2024-12-31 | $49.4M | $14.8M | +42.87% |
| 2023 | 2023-12-31 | $34.6M | $15.9M | +85.26% |
| 2022 | 2022-12-31 | $18.7M | $8.2M | +78.52% |
| 2021 | 2021-12-31 | $10.5M | −$14.2M | −57.54% |
| 2020 | 2020-12-31 | $24.6M | $22.9M | +1366.89% |
| 2019 | 2019-12-31 | $1.7M | — | — |
Maravai Lifesciences Holdings quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10.2M | $3.4M | +50.32% |
| Q1 2026 | 2026-03-31 | $6.7M | −$3.7M | −35.18% |
| Q4 2025 | 2025-12-31 | $3.9M | −$6.6M | −62.77% |
| Q3 2025 | 2025-09-30 | $9.1M | −$4.0M | −30.61% |
| Q2 2025 | 2025-06-30 | $6.8M | −$7.0M | −50.67% |
| Q1 2025 | 2025-03-31 | $10.4M | −$1.7M | −13.72% |
| Q4 2024 | 2024-12-31 | $10.5M | $1.2M | +12.88% |
| Q3 2024 | 2024-09-30 | $13.1M | $3.1M | +30.67% |
| Q2 2024 | 2024-06-30 | $13.8M | $4.5M | +48.44% |
| Q1 2024 | 2024-03-31 | $12.1M | $6.1M | +101.39% |
| Q4 2023 | 2023-12-31 | $9.3M | $3.3M | +55.83% |
| Q3 2023 | 2023-09-30 | $10.0M | $5.2M | +110.70% |
| Q2 2023 | 2023-06-30 | $9.3M | $5.0M | +115.23% |
| Q1 2023 | 2023-03-31 | $6.0M | $2.4M | +65.07% |
| Q4 2022 | 2022-12-31 | $6.0M | $3.8M | +168.83% |
| Q3 2022 | 2022-09-30 | $4.7M | $1.2M | +32.88% |
| Q2 2022 | 2022-06-30 | $4.3M | $1.9M | +80.78% |
| Q1 2022 | 2022-03-31 | $3.6M | $1.3M | +59.22% |
| Q4 2021 | 2021-12-31 | $2.2M | −$19.5M | −89.72% |
| Q3 2021 | 2021-09-30 | $3.6M | $1.7M | +92.92% |
| Q2 2021 | 2021-06-30 | $2.4M | $1.8M | +313.72% |
| Q1 2021 | 2021-03-31 | $2.3M | $1.8M | +348.43% |
| Q4 2020 | 2020-12-31 | $21.7M | — | — |
| Q3 2020 | 2020-09-30 | $1.8M | — | — |
| Q2 2020 | 2020-06-30 | $576,000 | — | — |
| Q1 2020 | 2020-03-31 | $508,000 | — | — |
Maravai Lifesciences Holdings stock-based compensation trends
Over the last five fiscal years, Maravai Lifesciences Holdings's stock-based compensation increased from $24.6M to $30.2M, a change of $5.5M. The latest reported quarter, Q2 2026, shows $10.2M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Maravai Lifesciences Holdings source filings ↗